NFKB1 and Parkinson disease: These findings indicated that fucoidan exerted its anti-peripheral and central inflammatory effects by modulating the gut microbiota to suppress LPS production and concurrently inhibiting the LPS/TLR4/NF-κB signaling pathway, suggesting a promising therapeutic approach targeting gut-derived inflammation and its transmission along the gut–brain axis in PD.